← Leaderboards
Charles M Rudin
University Of Chicago
$26,521,794
Attributed
$37,891,043
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,891,043 · 12
By mechanism
U24$11,732,558 · 1
R01$8,145,926 · 3
R35$5,214,420 · 1
UG1$5,068,500 · 1
P30$3,427,549 · 2
U01$2,746,451 · 1
Top collaborators
- David P Carbone7 shared
- John Thomas Poirier7 shared
- Helena Yu5 shared
- Lauren Averett Byers4 shared
- Ticiana Leal4 shared
- Jason S Lewis4 shared
- John D Minna4 shared
- Trudy Gale Oliver4 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Luis Bruno Barreiro$10,530,994
- Olufunmilayo I Olopade$31,360,913
- Mahesh P Gupta$12,529,486
- Daniel E Johnson$10,482,584
- Dezheng Huo$7,892,516
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsMalignant Neoplasm Of LungGrantResearch PersonnelMolecularIn VivoClinical TrialsTargeted TreatmentBaseCell LineNovel TherapeuticsClinical ResearchResistanceNovel StrategiesCohortPatient-Focused OutcomesLeadershipEpigenetic ProcessLung Small Cell CarcinomaLibrariesMeetingsChemotherapyRecurrence
Grant awards (60)
Coordinating center for the NCI small cell lung cancer research consortium$1,379,839
U24 · FY2025 · CA · contact PI
Novel therapeutic development for small cell lung cancer$1,062,000
R35 · FY2025 · CA · contact PI
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$683,484
UG1 · FY2025 · CA
Drivers of histologic transformation in EGFR-mutant lung cancer$404,888
R01 · FY2025 · CA
Coordinating center for the NCI small cell lung cancer research consortium$1,456,493
U24 · FY2024 · CA · contact PI
Novel therapeutic development for small cell lung cancer$1,008,900
R35 · FY2024 · CA · contact PI
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$683,484
UG1 · FY2024 · CA
Drivers of histologic transformation in EGFR-mutant lung cancer$384,644
R01 · FY2024 · CA
Coordinating center for the NCI small cell lung cancer research consortium$1,565,497
U24 · FY2023 · CA · contact PI
Novel therapeutic development for small cell lung cancer$1,040,760
R35 · FY2023 · CA · contact PI
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$621,608
UG1 · FY2023 · CA
Drivers of histologic transformation in EGFR-mutant lung cancer$396,790
R01 · FY2023 · CA
Coordinating center for the NCI small cell lung cancer research consortium$1,654,600
U24 · FY2022 · CA · contact PI
Novel therapeutic development for small cell lung cancer$1,040,760
R35 · FY2022 · CA · contact PI
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$734,389
UG1 · FY2022 · CA
Drivers of histologic transformation in EGFR-mutant lung cancer$396,790
R01 · FY2022 · CA
Coordinating center for the NCI small cell lung cancer research consortium$1,071,245
U24 · FY2021 · CA · contact PI
Novel therapeutic development for small cell lung cancer$1,062,000
R35 · FY2021 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zrrovalpituzumab, a DLL3-targeting monoclonal antibody$939,811
R01 · FY2021 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$742,329
UG1 · FY2021 · CA
Drivers of histologic transformation in EGFR-mutant lung cancer$404,888
R01 · FY2021 · CA
Coordinating center for the NCI small cell lung cancer research consortium$1,287,399
U24 · FY2020 · CA · contact PI
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$750,806
UG1 · FY2020 · CA
Determinants of acquired resistance in small cell lung cancer$607,259
R01 · FY2020 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zrrovalpituzumab, a DLL3-targeting monoclonal antibody$367,402
R01 · FY2020 · CA
Coordinating center for the NCI small cell lung cancer research consortium$1,043,471
U24 · FY2019 · CA · contact PI
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$852,400
UG1 · FY2019 · CA
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$630,572
R01 · FY2019 · CA
Determinants of acquired resistance in small cell lung cancer$611,353
R01 · FY2019 · CA · contact PI
Identification and validation of synthetic lethality in KRAS mutant lung adenocarcinoma patient derived xenografts$463,415
U01 · FY2019 · CA · contact PI
Coordinating center for the NCI small cell lung cancer research consortium$1,089,718
U24 · FY2018 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$699,927
R01 · FY2018 · CA
Determinants of acquired resistance in small cell lung cancer$619,653
R01 · FY2018 · CA · contact PI
Identification and validation of synthetic lethality in KRAS mutant lung adenocarcinoma patient derived xenografts$570,759
U01 · FY2018 · CA · contact PI
Coordinating center for the NCI small cell lung cancer research consortium$1,184,296
U24 · FY2017 · CA · contact PI
Determinants of acquired resistance in small cell lung cancer$619,653
R01 · FY2017 · CA · contact PI
Identification and validation of synthetic lethality in KRAS mutant lung adenocarcinoma patient derived xenografts$570,759
U01 · FY2017 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$446,668
R01 · FY2017 · CA
Determinants of acquired resistance in small cell lung cancer$615,628
R01 · FY2016 · CA · contact PI
CLINICAL RESEARCH OFFICE$613,631
P30 · FY2016 · CA · contact PI
Identification and validation of synthetic lethality in KRAS mutant lung adenocarcinoma patient derived xenografts$570,759
U01 · FY2016 · CA · contact PI
Protocol Review (CRC)$86,624
P30 · FY2016 · CA · contact PI
CLINICAL RESEARCH OFFICE$613,631
P30 · FY2015 · CA · contact PI
Identification and validation of synthetic lethality in KRAS mutant lung adenocarcinoma patient derived xenografts$570,759
U01 · FY2015 · CA · contact PI
Protocol Review (CRC)$86,624
P30 · FY2015 · CA · contact PI
CLINICAL RESEARCH OFFICE$588,914
P30 · FY2014 · CA · contact PI
Protocol Review (CRC)$83,131
P30 · FY2014 · CA · contact PI
CLINICAL RESEARCH OFFICE$573,748
P30 · FY2013 · CA · contact PI
Protocol Review (CRC)$80,991
P30 · FY2013 · CA · contact PI
CLINICAL RESEARCH OFFICE$613,631
P30 · FY2012 · CA · contact PI
Protocol Review (CRC)$86,624
P30 · FY2012 · CA · contact PI
Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small$317,239
R21 · FY2008 · CA · contact PI
Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small$317,087
R21 · FY2007 · CA · contact PI
A pharmacogenetic and pharmacodynamic study of erlotinib$189,865
R21 · FY2004 · CA
A pharmacogenetic and pharmacodynamic study of erlotinib$212,724
R21 · FY2003 · CA
GENETIC AND GENOMIC RESPONSES TO DNA DAMAGE$83,252
K08 · FY2003 · CA
GENETIC AND GENOMIC RESPONSES TO DNA DAMAGE$46,429
K08 · FY2003 · CA
GENETIC AND GENOMIC RESPONSES TO DNA DAMAGE$129,681
K08 · FY2002 · CA
GENETIC AND GENOMIC RESPONSES TO DNA DAMAGE$129,681
K08 · FY2001 · CA
GENETIC AND GENOMIC RESPONSES TO DNA DAMAGE$129,681
K08 · FY2000 · CA